We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

231 hedge funds and large institutions have $3.86B invested in Neurocrine Biosciences in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 67 increasing their positions, 96 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

496% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $13.9M

91% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 22

12% more capital invested

Capital invested by funds: $3.44B → $3.86B (+$423M)

9% more funds holding

Funds holding: 212 → 231 (+19)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

30% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 96

Holders
231
Holders Change
+19
Holders Change %
+8.96%
% of All Funds
6.16%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.19%
New
42
Increased
67
Reduced
96
Closed
22
Calls
$82.9M
Puts
$13.9M
Net Calls
+$69M
Net Calls Change
+$62.4M

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$44.1M
2
SIG
Senator Investment Group
New York
+$39.1M
3
American Century Companies
American Century Companies
Missouri
+$34M
4
JP Morgan Chase
JP Morgan Chase
New York
+$27.2M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$23.6M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$85.6M
2
BFA
BlackRock Fund Advisors
California
-$58.9M
3
Citadel Advisors
Citadel Advisors
Florida
-$40.4M
4
O
OrbiMed
New York
-$38.6M
5
Invesco
Invesco
Georgia
-$35.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
126
Tocqueville Asset Management
New York
$1.95M +$82.9K +1,800 +4%
HI
127
HBK Investments
Texas
$1.92M +$1.27M +27,679 +190%
ACP
128
Acuta Capital Partners
California
$1.91M +$1.93M +42,000 New
PI
129
Putnam Investments
Massachusetts
$1.86M -$1.78M -38,556 -49%
RPAM
130
Rhenman & Partners Asset Management
Sweden
$1.82M -$921K -20,000 -33%
CAM
131
ClariVest Asset Management
California
$1.8M +$244K +5,300 +15%
OAC
132
OMERS Administration Corp
Ontario, Canada
$1.77M +$1.8M +39,000 New
FAM
133
Fred Alger Management
New York
$1.73M -$2.38M -51,598 -58%
Barclays
134
Barclays
United Kingdom
$1.66M +$604K +13,129 +56%
ACI
135
Alpha Cubed Investments
California
$1.64M – – –
D.E. Shaw & Co
136
D.E. Shaw & Co
New York
$1.61M +$301K +6,541 +23%
WMSA
137
Weiss Multi-Strategy Advisers
New York
$1.43M +$16K +347 +1%
MAP
138
Moody Aldrich Partners
Massachusetts
$1.41M +$973K +21,125 +215%
LOAMU
139
Lombard Odier Asset Management (USA)
New York
$1.4M +$272K +5,914 +24%
ACM
140
Asymmetry Capital Management
California
$1.39M -$1.5M -32,517 -51%
PAM
141
Panagora Asset Management
Massachusetts
$1.38M -$328K -7,125 -19%
Handelsbanken Fonder
142
Handelsbanken Fonder
Sweden
$1.36M +$1.38M +30,000 New
ARTA
143
A.R.T. Advisors
New York
$1.32M +$1.34M +29,173 New
CSS
144
Cubist Systematic Strategies
Connecticut
$1.25M -$952K -20,680 -43%
WC
145
Wexford Capital
Florida
$1.23M – – –
JMPWA
146
JP Morgan Private Wealth Advisors
California
$1.18M -$27.1K -589 -2%
Jane Street
147
Jane Street
New York
$1.17M +$420K +9,127 +55%
BC
148
Birchview Capital
Vermont
$1.15M – – –
AQR Capital Management
149
AQR Capital Management
Connecticut
$1.14M -$187K -4,069 -14%
IGIM
150
I.G. Investment Management
Manitoba, Canada
$1.09M -$1.52M -33,000 -58%
4 5
6
7 8

NBIX Hedge Fund Activity: Q2 2016 in Review

231 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2016, worth a combined $3.86B — up 12% from $3.44B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new NBIX positions and 22 closed out — a net gain of 20 holders — while 67 added to existing stakes and 96 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $44.1M. The largest seller was Visium Asset Management, cutting an estimated $85.6M.

  • 231 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2016, up from 212 in Q1 2016.
  • Funds reported $3.86B of Neurocrine Biosciences stock for Q2 2016, up 12% quarter-over-quarter.
  • 42 funds opened new Neurocrine Biosciences positions in Q2 2016 and 22 closed out, a net change of +20 holders.
  • The largest Neurocrine Biosciences buyer in Q2 2016 was AllianceBernstein, an estimated $44.1M added.
  • The largest Neurocrine Biosciences seller in Q2 2016 was Visium Asset Management, an estimated $85.6M sold.

Based on aggregated 13F filings for Q2 2016.